Funding profile · Drug discovery platforms

Forcyte Biotechnologies

Two SEC filings five days apart, eleven NIH grants, and a company total of $5.7 million that the filings do not come close to reaching. Most of the documented money is federal.

$5.7MTotal raised including public support, company-reported June 2022
$3.19MNIH grants on record, 56% of the company total
$160KEquity sold of $2.0M offered, per the amended Form D
3Investors in the only Regulation D offering on file

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2018 to 2022 NIH SBIR and STTR awards $3,185,607 NCATS, NCCIH, NICHD, NIGMS, NIDDK NIH
Dec 2018 Regulation D offering, options to acquire equity $2.0M offered; $160,000 sold 3, not named Form D and D/A
Winter 2021 Y Combinator batch W21 Not disclosed Y Combinator Accelerator listing
Jun 2022 New funding, amount not disclosed Not disclosed; total stated as $5.7M Milestone View, Pioneer Fund, Acequia Capital, Y Combinator, Jude Gomila and others Company release
After Jun 2022 No further round announced or filed None on record None Not found

What the filings show

Forcyte Biotechnologies, Inc. · Form D · filed Jan 10, 2019

First sale
Dec 18, 2018
Offered
$2,000,000
Sold
$1,000,000 · $1,000,000 remaining
Investors
3 · average about $333,333
Security
Option to acquire equity · minimum investment $25,000
Exemption
Rule 506(b)
Issuer size
No revenues · incorporated in Delaware, 2017
Related persons
Ivan Pushkarsky (executive officer). Signed by Leonard Joseph Nannarone, General Counsel
Filing
SEC EDGAR, CIK 0001760069

Forcyte Biotechnologies, Inc. · Form D/A · filed Jan 15, 2019

Amends
Accession 0001760069-19-000001
First sale
Dec 18, 2018, unchanged
Offered
$2,000,000, unchanged
Sold
$160,000 · $1,840,000 remaining
Investors
3 · average about $53,333
Exemption
Rule 506(b)
Related persons
Ivan Pushkarsky (executive officer). Same signer
Filing
SEC EDGAR, CIK 0001760069. No later filing of any type

Reading the filings

  1. The first filing overstated the raise by a factor of six.Sold went from $1,000,000 to $160,000 in five days with the investor count unchanged at three. Per investor that is a move from about $333,333 to about $53,333. The Los Angeles Business Journal reported the correction the same week: “An attorney representing Forcyte Biotechnologies updated the securities filing on Jan. 15, after realizing the earlier filing was made in error, said company founder Ivan Pushkarsky.” The newspaper had already published the $1 million figure.
  2. Most of the capital on record is taxpayer money.Of the $5.7M the company claimed in June 2022, $3,185,607 is NIH grant money that can be counted award by award. That is about 56 percent. The remaining $2.5M is the company’s own arithmetic and is not supported by any filing.
  3. The 2022 round has no Form D.Five named backers were announced on June 1, 2022 and nothing was filed. An issuer relying on Section 4(a)(2) rather than Regulation D files no Form D, so the absence does not mean no money moved. It does mean the round size, the investor count and the security type are unverifiable.
  4. What was sold was not stock.The 2019 filing checks only the option to acquire equity box, with a $25,000 minimum. That is the signature of SAFEs or convertible notes, which is to say the company had not been priced by an outside lead at that point.
  5. The cap table was one person deep.Both filings list a single related person, Ivan Pushkarsky, as executive officer. No outside directors appear. Three years later a Y Combinator batch and five named investors had arrived, and still no filing recorded a board.
  6. The data providers do not agree on anything.CB Insights puts total raised at $130K and marks the company alive. Tracxn puts it at $5.7M across eight rounds and shows 8 employees as of June 2026. Seedtable dates the last funding to August 23, 2021, marks the status closed, and states that the founder reports operations were wound down. The SEC record supports only $160,000.

Commercial signals

Signal Detail Source type
Grants 11 NIH awards, $3,185,607, FY2018 to FY2022. Last project end date on file: Aug 31, 2023. No NSF award found. Public record
Intellectual property US 11,592,438 issued Feb 28, 2023 to The Regents of the University of California. Forcyte held a license, not title. Public record
Revenue An SBIR profile last edited Sep 2021 puts the company in a $0.5M to $1M revenue band with 5 to 9 employees. Never confirmed by the company. Third party
Partnerships Collaborations with multiple biopharma companies including “an ongoing partnership with an undisclosed leading pharmaceutical company”. No partner named, no terms given. Company-stated
Products FLECS 384-well assay plates and kits sold for research use, documented in a Molecular Devices application note. Partner-stated
Clinical assets No registered trials, no FDA records, no named target. Pipeline entries all read “Novel Undisclosed”. Not found
Operating status Last dated company post Aug 1, 2023. Last archived home page returning 200: Jan 14, 2026. On Sep 23, 2026 the domain served a certificate for *.sucuri.net, not for forcytebio.com. A contact database dates the founder’s chief executive role 2017 to 2026 and places him at BioRender from 2026. Independent

What to watch

  • A Form D that never came. Nothing has been filed under CIK 0001760069 since January 15, 2019, which is the cleanest single fact on this page.
  • A Delaware dissolution or a California franchise tax forfeiture, either of which would date the wind-down precisely.
  • The status of the UCLA license on patent family 11,592,438. A reassignment or a new licensee would say where the technology went.
  • Any acquirer of the FLECS consumables line. The plates had outside users and could outlive the corporate entity.

The Forcyte Biotechnologies story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • SFA Therapeutics: Shared investor: Acequia Capital. A Temple University spinout turning short chain fatty acids from the human gut into oral pills
  • Adaptyv Bio: Shared investor: Acequia Capital. A Swiss automated laboratory that turns AI designed protein sequences into measured binding data, and that has published the full results of three open design
  • PipeBio: Shared investor: Acequia Capital. A five person Danish company that built cloud bioinformatics for antibody discovery, got its name into the methods sections of twenty published papers, and was bought by
  • Legion Health: Shared investor: Acequia Capital. An AI native psychiatry clinic holding the second agreement Utah has ever signed to let software authorize a prescription renewal

Sources

  1. Public recordForm D, Forcyte Biotechnologies, Inc.SEC EDGAR, CIK 0001760069 · Jan 10, 2019
  2. Public recordForm D/A, Forcyte Biotechnologies, Inc.SEC EDGAR, CIK 0001760069 · Jan 15, 2019
  3. Public recordNIH RePORTER, 11 awards to Forcyte Biotechnologies, Inc.NIH · FY2018 to FY2022
  4. Public recordUS Patent 11,592,438, assigned to The Regents of the University of CaliforniaUSPTO · Feb 28, 2023
  5. IndependentUPDATE: Brentwood-Based Forcyte Biotechnologies Targets $2M RaiseLos Angeles Business Journal · Jan 14, 2019
  6. IndependentForcyte Biotechnologies Secures Funding; Totals $5.7MFinSMEs · Jun 2, 2022
  7. IndependentMechano-therapeutics Discovery Startup Forcyte Bio Secures New FundingBioSpace · Jun 1, 2022
  8. IndependentForcyte Biotechnologies company profile, status closedSeedtable · accessed Sep 23, 2026
  9. IndependentForcyte Biotechnologies financials and Y Combinator W21 collectionCB Insights · accessed Sep 23, 2026
  10. IndependentForcyte Biotechnologies funding, team and employee countTracxn · accessed Sep 23, 2026
  11. IndependentForcyte Biotechnologies Inc SBIR company profileInknowvation · last edited Sep 8, 2021
  12. CompanyForcyte Bio Secures New Funding From Y Combinator and OthersBusiness Wire · Jun 1, 2022
  13. CompanyThe body is (also) a mechanical systemForcyte Bio blog · Aug 1, 2023
  14. PartnerHigh-throughput screening of single-cell contractile force using FLECS TechnologyMolecular Devices application note

Compiled from SEC, NIH, USPTO and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Forcyte Biotechnologies. This page is not an offer to sell or a recommendation to buy any security.